Mario Cazzola
Mario Cazzola
Professore Onorario di Malattie Respiratorie
Verified email at
Cited by
Cited by
Outcomes for COPD pharmacological trials: from lung function to biomarkers
M Cazzola, W MacNee, FJ Martinez, KF Rabe, LG Franciosi, PJ Barnes, ...
European Respiratory Journal 31 (2), 416-469, 2008
Pharmacology and therapeutics of bronchodilators
M Cazzola, CP Page, L Calzetta, MG Matera
Pharmacological reviews 64 (3), 450-504, 2012
Symptom variability in patients with severe COPD: a pan-European cross-sectional study
R Kessler, MR Partridge, M Miravitlles, M Cazzola, C Vogelmeier, ...
European Respiratory Journal 37 (2), 264-272, 2011
Outdoor air pollution, climatic changes and allergic bronchial asthma
G D'Amato, G Liccardi, M D'amato, M Cazzola
European Respiratory Journal 20 (3), 763-776, 2002
The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
M Cazzola, M Molimard
Pulmonary pharmacology & therapeutics 23 (4), 257-267, 2010
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
M Cazzola, F Imperatore, A Salzillo, F Di Perna, F Calderaro, ...
Chest 114 (2), 411-415, 1998
Markers of disease severity in chronic obstructive pulmonary disease
LG Franciosi, CP Page, BR Celli, M Cazzola, MJ Walker, M Danhof, ...
Pulmonary pharmacology & therapeutics 19 (3), 189-199, 2006
β2-agonist therapy in lung disease
M Cazzola, CP Page, P Rogliani, MG Matera
American journal of respiratory and critical care medicine 187 (7), 690-696, 2013
The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy
G D'amato, G Liccardi, M D'amato, M Cazzola
Respiratory medicine 95 (7), 606-611, 2001
Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study
M Cazzola, MG Matera, G Santangelo, A Vinciguerra, F Rossi, G D'amato
Respiratory medicine 89 (5), 357-362, 1995
Prevalence of comorbidities in patients with chronic obstructive pulmonary disease
M Cazzola, G Bettoncelli, E Sessa, C Cricelli, G Biscione
Respiration 80 (2), 112-119, 2010
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
M Cazzola, F Di Marco, P Santus, B Boveri, M Verga, MG Matera, ...
Pulmonary pharmacology & therapeutics 17 (1), 35-39, 2004
Night-time symptoms: a forgotten dimension of COPD
A Agusti, J Hedner, JM Marin, F BarbÚ, M Cazzola, S Rennard
European Respiratory Review 20 (121), 183-194, 2011
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD
F Di Marco, J Milic-Emili, B Boveri, P Carlucci, P Santus, F Casanova, ...
European Respiratory Journal 21 (1), 86-94, 2003
β2‐adrenoceptor agonists: current and future direction
M Cazzola, L Calzetta, MG Matera
British journal of pharmacology 163 (1), 4-17, 2011
Novel long‐acting bronchodilators for COPD and asthma
M Cazzola, MG Matera
British journal of pharmacology 155 (3), 291-299, 2008
Integrated care pathways for airway diseases (AIRWAYS-ICPs)
J Bousquet, A Addis, I Adcock, I Agache, A Agusti, A Alonso, ...
European Respiratory Journal 44 (2), 304-323, 2014
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD
L Calzetta, P Rogliani, MG Matera, M Cazzola
Chest 149 (5), 1181-1196, 2016
Inhaled β2-Adrenoceptor Agonists
M Cazzola, MG Matera, CF Donner
Drugs 65 (12), 1595-1610, 2005
Oxidized BAL fluid proteins in patients with interstitial lung diseases
AG Lenz, U Costabel, KL Maier
European Respiratory Journal 9 (2), 307-312, 1996
The system can't perform the operation now. Try again later.
Articles 1–20